CAJ | 학술논문

目的：观察麦芽提取物对高泌乳素血症大鼠垂体泌乳素( PRL)表达及乳腺组织形态学的影响。方法大鼠背部皮下注射盐酸甲氧氯普胺制备高泌乳素血症模型。60只大鼠分为正常对照组、模型对照组、溴隐亭组及麦芽提取物大、中和小剂量组。除正常对照组外,其他组进行造模。溴隐亭组给予溴隐亭0.389 mg·kg-1·d-1；麦芽提取物小、中和大剂量组分别给予麦芽提取物7.98,15.96和31.92 g·kg-1·d-1。正常对照组和模型对照组给予等容量纯化水。大鼠在造模成功后,灌胃给予相应的药物进行治疗给药,每次2 mL,每日1次,连续30 d。对大鼠脑垂体PRL阳性细胞进行计数,采用反转录聚合酶链反应( RT-PCR)检测大鼠垂体PRL mRNA的表达水平,以及采用免疫组化法观察乳腺组织形态学的变化。结果正常对照组、模型对照组、溴隐亭组、麦芽提取物大、中和小剂量组的PRL阳性细胞数量分别为(2.4±0.3),(21.7±0.8),(3.8±0.5),(4.5±0.4),(6.7±0.5),(15.8±1.2)个,PRL mRNA表达水平分别为(0.31±0.02),(1.58±0.06),(0.45±0.04),(0.49±0.03),(0.61±0.04),(0.95±0.09)。与正常对照组比较,模型对照组大鼠脑垂体PRL阳性细胞数量和PRL mRNA表达水平显著增加(P<0.01),同时乳腺组织出现增生。与模型对照组比较,麦芽提取物大、中剂量组大鼠脑垂体PRL阳性细胞数量和PRL mRNA表达水平显著减少(P<0.01),而且乳腺增生明显减轻。结论麦芽提取物能有效治疗高泌乳素血症及抑制乳腺组织的增生,作用机制是其显著降低高泌乳素血症大鼠脑垂体PRL的表达。
목적：관찰맥아제취물대고비유소혈증대서수체비유소( PRL)표체급유선조직형태학적영향。방법대서배부피하주사염산갑양록보알제비고비유소혈증모형。60지대서분위정상대조조、모형대조조、추은정조급맥아제취물대、중화소제량조。제정상대조조외,기타조진행조모。추은정조급여추은정0.389 mg·kg-1·d-1；맥아제취물소、중화대제량조분별급여맥아제취물7.98,15.96화31.92 g·kg-1·d-1。정상대조조화모형대조조급여등용량순화수。대서재조모성공후,관위급여상응적약물진행치료급약,매차2 mL,매일1차,련속30 d。대대서뇌수체PRL양성세포진행계수,채용반전록취합매련반응( RT-PCR)검측대서수체PRL mRNA적표체수평,이급채용면역조화법관찰유선조직형태학적변화。결과정상대조조、모형대조조、추은정조、맥아제취물대、중화소제량조적PRL양성세포수량분별위(2.4±0.3),(21.7±0.8),(3.8±0.5),(4.5±0.4),(6.7±0.5),(15.8±1.2)개,PRL mRNA표체수평분별위(0.31±0.02),(1.58±0.06),(0.45±0.04),(0.49±0.03),(0.61±0.04),(0.95±0.09)。여정상대조조비교,모형대조조대서뇌수체PRL양성세포수량화PRL mRNA표체수평현저증가(P<0.01),동시유선조직출현증생。여모형대조조비교,맥아제취물대、중제량조대서뇌수체PRL양성세포수량화PRL mRNA표체수평현저감소(P<0.01),이차유선증생명현감경。결론맥아제취물능유효치료고비유소혈증급억제유선조직적증생,작용궤제시기현저강저고비유소혈증대서뇌수체PRL적표체。
Objective To observe the effects of malt extract on prolactin expression and morphology of mammary tissue in hyperprolactinemia rats. Methods Metoclopramide hydrochloride was injected subcutaneously to establish hyperprolactinemia model. Sixty rats were divided into normal control group, model control group, bromocriptine group, high-dose, middle-dose and low-dose malt extract groups. Except normal control group, hyperprolactinemia model was established in the other groups. Bromocriptine (0. 389 mg·kg-1 ·d-1 ) was given to bromocriptine group. Malt extract (7. 98, 15. 96 and 31. 92 g·kg-1 ·d-1 ) was administered in low-dose, middle-dose and high-dose malt extract groups. Equal volume of purified water was given to normal control group and model control group. After 30 days of administration, PRL positive cell number of rat hypophysis was counted. RT-PCR was used to measure hypophysis PRL mRNA expression, and morphology of mammary tissues was observed by immunohistochemical method. Results PRL positive cell number was (2. 4±0. 3), (21. 7±0. 8), (3. 8± 0. 5), (4. 5±0. 4), (6. 7±0. 5) and (15. 8±1. 2) in normal control group, model control group, bromocriptine group, high-dose, middle-dose and low-dose malt extract groups. PRL mRNA expression level was (0. 31±0. 02), (1. 58±0. 06), (0. 45± 0. 04), (0. 49±0. 03), (0. 61±0. 04), and (0. 95±0. 09), respectively. As compared with normal control group, hypophysis PRL positive cell number and PRL mRNA expression level of high-dose and middle-dose malt extract group were increased significantly (P<0. 01), and hyperplasia of mammary glands appeared. As compared with model control group, hypophysis PRL positive cell number and PRL mRNA expression level of high-dose and middle-dose malt extract group was decreased significantly (P<0. 01), and hyperplasia of mammary glands was alleviated obviously. Conclusion Malt extract can effectively treat hyperprolactinemia and inhibit hyperplasia of mammary glands through significantly decreasing the expression of hypophysis prolactin in hyperprolactinemia rats.